- Home
- GRNT vs AUPH Comparison
GRNT vs AUPH Comparison
Compare GRNT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRNT
- AUPH
- Stock Information
- Founded
- GRNT 2013
- AUPH 1993
- Country
- GRNT United States
- AUPH Canada
- Employees
- GRNT N/A
- AUPH N/A
- Industry
- GRNT Blank Checks
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- GRNT Finance
- AUPH Health Care
- Exchange
- GRNT Nasdaq
- AUPH Nasdaq
- Market Cap
- GRNT 707.4M
- AUPH 1.4B
- IPO Year
- GRNT N/A
- AUPH 1999
- Fundamental
- Price
- GRNT $5.40
- AUPH $12.82
- Analyst Decision
- GRNT Buy
- AUPH Strong Buy
- Analyst Count
- GRNT 2
- AUPH 3
- Target Price
- GRNT $7.50
- AUPH $12.00
- AVG Volume (30 Days)
- GRNT 569.3K
- AUPH 1.6M
- Earning Date
- GRNT 11-06-2025
- AUPH 11-06-2025
- Dividend Yield
- GRNT 8.19%
- AUPH N/A
- EPS Growth
- GRNT N/A
- AUPH N/A
- EPS
- GRNT 0.25
- AUPH 0.42
- Revenue
- GRNT $409,332,000.00
- AUPH $260,111,000.00
- Revenue This Year
- GRNT $34.49
- AUPH $16.92
- Revenue Next Year
- GRNT $13.97
- AUPH $14.43
- P/E Ratio
- GRNT $21.83
- AUPH $30.31
- Revenue Growth
- GRNT 10.32
- AUPH 25.59
- 52 Week Low
- GRNT $4.52
- AUPH $6.43
- 52 Week High
- GRNT $7.00
- AUPH $12.87
- Technical
- Relative Strength Index (RSI)
- GRNT 49.65
- AUPH 68.97
- Support Level
- GRNT $5.19
- AUPH $12.06
- Resistance Level
- GRNT $5.47
- AUPH $12.82
- Average True Range (ATR)
- GRNT 0.17
- AUPH 0.37
- MACD
- GRNT -0.01
- AUPH -0.04
- Stochastic Oscillator
- GRNT 33.56
- AUPH 93.98
About GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.